Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

COSCIENS Biopharma Inc T.CSCI

Alternate Symbol(s):  CSCI

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.


TSX:CSCI - Post by User

Comment by prophetoffactzon Aug 30, 2024 9:00am
50 Views
Post# 36202503

RE:PGX-Whey

RE:PGX-WheyPGX Technology applied to whey has several commercial applications, primarily in the food, nutraceutical, and pharmaceutical industries. The key applications include:
  • Whey Protein Concentrates: PGX Technology efficiently concentrates whey proteins such as β-lactoglobulin, α-lactalbumin, and bovine serum albumin while significantly reducing lactose content. This results in high-quality whey protein concentrates that can be used in various food products, enhancing their nutritional profile and functionality.
  • Functional Foods: The concentrated whey proteins produced via PGX can be incorporated into functional foods aimed at improving health benefits, such as muscle recovery and weight management. The high solubility and favorable physicochemical properties of PGX-processed whey proteins make them suitable for use in protein bars, beverages, and dietary supplements.
  • Nutraceuticals: The ability to produce whey protein powders with specific functional attributes allows for the development of nutraceutical products that target specific health outcomes, such as improved gut health or enhanced immune function. These products can leverage the bioactive properties of whey proteins while minimizing undesirable components like lactose.
  • Pharmaceutical Applications: PGX Technology can be utilized to create drug delivery systems using whey proteins as carriers for active pharmaceutical ingredients (APIs). The porous structure of PGX-processed whey proteins can enhance the solubility and bioavailability of drugs, making them more effective in therapeutic applications.
  • Sustainable Production: The mild processing conditions of PGX Technology contribute to its sustainability, allowing for the efficient use of whey, a byproduct of cheese production. This aligns with industry trends towards waste reduction and valorization of food byproducts, making PGX-processed whey proteins an environmentally friendly option.
Overall, PGX Technology's ability to produce high-quality, concentrated whey protein products with enhanced functional properties positions it as a valuable tool in the development of innovative food and health products.
<< Previous
Bullboard Posts
Next >>